{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:06:21Z","timestamp":1790024781892,"version":"4.0.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have been widely applicated in clinical therapy in recent years. Skin-related adverse reaction is one of the most common adverse events for ICIs. Stevens-Johnson syndrome (SJS) is one of the serious cutaneous reactions threatening the life. Here, we reported a case of 76-year-old male patient with poorly differentiated metastatic lung adenocarcinoma, after 9 weeks exposure of sintilimab (3 doses) combined with paclitaxel liposome after concurrent chemotherapy\/radiotherapy, experienced Stevens-Johnson syndrome involving limbs, trunk, lip and the oral mucosa. Biopsy of the skin tissue showed infiltration of CD4 and CD8 positive T lymphocytes. We also found PD-L1 expression in the glands and the basal layer of the skin. This finding is distinct from the previously reported expression of PD-L1 on the surface of epidermal keratinocytes in patients with SJS due to immunotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2023.912168","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:15:30Z","timestamp":1694754930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Xueqin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diangang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxi","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.03.026","article-title":"Pembrolizumab-induced Stevens\u2013Johnson syndrome in non-melanoma patients","volume":"81","author":"Saw","year":"2017","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000326","article-title":"Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome","volume":"27","author":"Mirza","year":"2017","journal-title":"Melanoma Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13810","article-title":"Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy","volume":"44","author":"Nomura","year":"2017","journal-title":"J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jtos.2021.06.010","article-title":"Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome\/toxic epidermal necrolysis in cancer patients","volume":"22","author":"Ma","year":"2021","journal-title":"Ocul Surf"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-019-00111-8","article-title":"Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment","volume":"28","author":"Paulmann","year":"2019","journal-title":"Allergo J Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14530","article-title":"UK Guidelines for the management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"174","author":"Creamer","year":"2016","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14711","article-title":"Epidermal necrolysis in the context of immuno-oncologic medication as well as kinase inhibitors and biologics","volume":"20","author":"Ziemer","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13876","article-title":"Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions","volume":"17","author":"Reschke","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317105","article-title":"Human leucocyte antigen association of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications in Han Chinese","volume":"106","author":"Ma","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-induced autoimmune diabetes in a patient with the anti-tumor effect of partial regression","volume":"11","author":"Wen","year":"2020","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-1310","article-title":"An esophageal cancer case of cytokine release syndrome with multiple-organ injury induced by an anti-PD-1 drug: a case report","volume":"9","author":"Gao","year":"2020","journal-title":"Ann Palliat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.12.030","article-title":"Marked elevation of creatine phosphokinase alone caused by sintilimab beware of hypothyroid myopathy","volume":"128","author":"Ni","year":"2020","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000314","article-title":"Paraneoplastic encephalitis and enteric neuropathy associated with anti-Hu antibody in a patient following immune-checkpoint inhibitor therapy","volume":"43","author":"Kang","year":"2020","journal-title":"J Immunother"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13217","article-title":"Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab","volume":"45","author":"Hu","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872","article-title":"Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy","volume":"22","author":"Goldinger","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000001816","article-title":"Immunohistochemical expression of PD-L1 is increased in lesional epidermal keratinocytes in Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"43","author":"Ziemer","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0218","article-title":"Challenges faced when identifying patients for combination immunotherapy","volume":"13","author":"Ernstoff","year":"2017","journal-title":"Future Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0422","article-title":"The evolving role of immune checkpoint inhibitors in cancer treatment","volume":"20","author":"Pennock","year":"2015","journal-title":"Oncologist"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.912168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T05:15:33Z","timestamp":1694754933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.912168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":25,"alternative-id":["10.3389\/fonc.2023.912168"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.912168","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"article-number":"912168"}}